Biodesix, Inc., a Boulder, CO-based molecular diagnostic company dedicated to personalizing medicine, raised an additional $6.1m in Series E funding.
This added to the $8.3m first close of the round announced a month ago (read here) with proceeds now totalling $14.4m. Existing shareholders provided all funds and the offering will remain open to current shareholders until September of 2014.
The company intends to use the funds for ongoing development of its technology platform and expansion of sales and marketing efforts to support its first product, VeriStrat®, a serum protein test that helps physicians guide therapy for patients with advanced non-small cell lung cancer (NSCLC).
In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents.
02/12/2013: Biodesix Closes $8.3M Series E Equity Financing
12/04/2013: Biodesix Closes $8.8M Series D Financing
11/11/2010: Biodesix Receives $7.1M in Series C Financing Round